Synapse Open Synapse
Biology

Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal

BioPharma Dive · · 2 min read

New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.

Latest from BioPharma Dive